Stockhub

Cynata Therapeutics Limited: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 August 2022

  • curprev 08:0708:07, 19 August 2022 >Nick 1,223 bytes +1,223 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the..."
Retrieved from "https://stockhub.co/research/Cynata_Therapeutics_Limited"